

Special Issue

New Insights on Therapy in Hepatocellular Carcinoma

Message from the Guest Editor

Hepatocellular Carcinoma (HCC) remains a serious etiology of cancer-related mortality worldwide.

Chronic inflammation and repetitive liver injury (primarily due to hepatitis B and C virus) are the main etiologies of hepatocarcinogenesis. Meanwhile, cirrhosis has increasingly given rise to nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH). NASH often develops in obesity, type 2 diabetes, dyslipidemia and hypertension patients and represents an emerging major additional risk factor for HCC in the United States; it is anticipated to replace viral hepatitis as the most common etiology of HCC in the US. Current estimates suggest the prevalence of NASH ranges from 3 to 5%, indicating a large percentage of the general population is at high for both cirrhosis and HCC.

These mechanisms lead to repetitive liver injury and repair, progressive hepatic dysfunction and eventual end-stage liver disease with cirrhosis.

This Special Issue will highlight the current efficiency of diagnosis and treatment of HC and provide an overview of the current ongoing clinical trials addressing these challenges.

Guest Editor

Dr. Curtis J. Wray

McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA

Deadline for manuscript submissions

closed (1 November 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/117808

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)